Edotecarin clinical trials
How each study uses edotecarin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Edotecarin
- 5
Studies by the year they started
5 studies that test it; most in 2003 (4)
| Year | Studies |
|---|---|
| 2003 | 4 |
| 2004 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Often tested with
Tested in the same studies.
Cisplatin (1) · Temozolomide (1) · Carmustine (1) · Lomustine (1)
Studies
Open first, then newest update. How each study uses edotecarin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to ChemotherapyCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00070031Written as edotecarin
- Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00072332Written as edotecarin
- Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane TherapyCompletedPhase 2PfizerNCT00067314Written as Edotecarin
- Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma MultiformeCompletedPhase 3PfizerNCT00068952Written as Edotecarin
- Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After ChemotherapyCompletedPhase 2PfizerNCT00087503Written as Edotecarin
Codes
What other systems call edotecarin · ClinicalTrials.gg INT004180
- MeSH (NLM) C121395edotecarinOne source NLM
- UNII (FDA) 1V8X590XDPEDOTECARINConfirmed FDA, NLM, Wikidata
- Wikidata Q27095555edotecarinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2665EdotecarinOne source FDA
- DrugBank DB04882One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C121395 | edotecarin | One source NLM |
| UNII (FDA) | 1V8X590XDP | EDOTECARIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27095555 | edotecarin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2665 | Edotecarin | One source FDA |
| DrugBank | DB04882 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.